Earnings Poll: Genmab A/S third quarter results due on November 6
Nov 5 (Reuters) - (All figures in US Dollars) Genmab A/S GMAB.CO reports its third quarter results on November 6. Year to date, Genmab A/S shares are up 24.92%. Below is a table of quarterly and annual analyst estimates for results based on LSEG data.
| Qtr. to September 2025 | No. of analysts | Mean Estimate |
|---|---|---|
| Revenue | 10 | 991.17 million |
| Pre-tax profit | 6 | 377.94 million |
| EPS | 8 | 4.64 |
| EBIT | 8 | 379.51 million |
| Net Profit | 7 | 297.86 million |
| Year to December 2025 | No. of Analysts | Mean Estimate |
|---|---|---|
| Revenue | 18 | 3.66 billion |
| Pre-tax profit | 15 | 1.36 billion |
| EPS | 16 | 16.94 |
| EBITDA | 13 | 1.38 billion |
| EBIT | 16 | 1.24 billion |
| Net Profit | 16 | 1.07 billion |
| Dividend | 12 | 0.00 |
| Net Debt | 10 | -3.13 billion |
Recent news on Genmab A/S
See all newsBrief: Genmab Says Orbis Investment Management Holds 4.99% Of Genmab Voting Rights As Of June 12
Brief: Genmab Announces Epcoritamab Monotherapy And Epcoritamab-Based Combination Regimens Demonstrate High Response Rates In Elderly Patients With Newly Diagnosed Diffuse Large B-Cell Lymphoma
Brief: Genmab Presents Epcore Fl-1 Data Showing Consistent Efficacy, Safety For Epcoritamab Combination
Brief: Genmab Says Orbis Investment Management Limited Holds 5.08% Of Genmab A/S As Of May 8, 2026
Genmab falls after 'uneventful' Q1, profit miss